P-glycoprotein and Cytochrome P450 3A4 interaction (P-gp/CYP3A4 interaction)

The pharmacokinetic interaction via P-glycoprotein (P-gp) and Cytochrome P450 3A4 (CYP3A4) represents a fundamental mechanism of the body's defense against xenobiotics, primarily occurring in the small intestine and liver (Benet et al., 2004, PMID: 15102874). P-gp, an ATP-binding cassette transporter encoded by the ABCB1 gene, acts as an efflux pump on the apical membrane of enterocytes, while CYP3A4 is the primary Phase I enzyme responsible for the oxidative metabolism of approximately 50% of marketed drugs (NIH PubChem, 2024). These two proteins share a high degree of substrate specificity and are co-localized, leading to a synergistic interplay where P-gp-mediated efflux cycles drug molecules back into the intestinal lumen, thereby increasing their exposure to intracellular CYP3A4 and enhancing first-pass metabolism (Cummins et al., 2002, PMID: 11934856). This interaction is a major determinant of the low and variable bioavailability of many drugs, such as immunosuppressants and protease inhibitors. Clinically, this pathway is a frequent site of drug-drug interactions (DDIs); for instance, the inhibition of both P-gp and CYP3A4 by drugs like ritonavir or ketoconazole can lead to toxic systemic levels of shared substrates (FDA DDI Guidance, 2020). Conversely, induction by agents like rifampin can significantly reduce therapeutic efficacy, posing a major challenge in polypharmacy and narrow therapeutic index drug management.

Other names

P-gp/CYP3A4 interplayABCB1 and CYP3A4 synergyIntestinal first-pass metabolism interplayMDR1 and CYP3A4 interaction

Synergistic reduction of drug bioavailability through repeated cycles of apical efflux and intracellular metabolism.